The World Health Organization (WHO)’s global hepatitis strategy aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030, with the goal of eliminating viral hepatitis as a public health threat by 2030.
At Gilead, we are dedicated to supporting the WHO’s ambitious goal to eliminate viral hepatitis as a public health threat by 2030. We believe that empowered communities and peer support are crucial in strengthening healthcare systems and increasing access to services. Through the global All4Liver grant, we aim to amplify the voices of those affected, foster resilience and drive collection action.
ALL4LIVER Grant
Test. Link. Prioritize. Striving for global viral hepatitis elimination by 2030
Launched in 2021, the biennial All4LIVER Grant supports local communities to enhance education about viral hepatitis across Asia. In 2023, the grant expands globally (excluding the United States). WHO estimates that 296 million people were living with HBV in 2019 and 1.5 million new infections each year.[4]
Furthermore, the global burden is intensified by the hepatitis D virus (HDV), which co-infects nearly 5% of individuals with HBV. In 2019 alone, hepatitis C (HCV) caused approximately 290,000 deaths, primarily due to complications like cirrhosis and hepatocellular carcinoma.[5]
PARTNERING TO ELIMINATE HEPATITIS IN ASIA
FIGHTING HEPATITIS WITH KNOWLEDGE AND ACTION
HEP CAN’T WAIT ASIA WORKSHOP
The Hep Can’t Wait Asia Workshop is a collaboration between the World Hepatitis Alliance and Gilead Sciences, bringing together the voices of community organizations across Asia-Pacific to map our road ahead towards viral hepatitis elimination by 2030.
LIVER INDEX FINDINGS
KEY GAPS IN VIRAL HEPATITIS AWARENESS#
1 in 2
people had not heard of hepatitis C
Only 1 in 3
people are aware of the various stages of liver scarring or fibrosis
1 in 2
people misunderstood that hepatitis B and hepatitis C are transmitted by dining with an infected person
AREAS FOR IMPROVEMENT IN ATTITUDES TOWARDS SCREENING AND DIAGNOSIS#
Only 4 in 10
people had their health screening in the last 12 months
Only 4 in 10
people are aware of the available tests to diagnose hepatitis B and hepatitis C
# Lee, M.H., Ahn, S.H., Chan, H.L., Choudhry, A., Alvani Gani, R., Mohamed, R., Ong, J.P., Shukla, A., Tan, C.K., Tanwandee, T. and Thuy, P.T.T., 2022. Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study. Journal of Viral Hepatitis, 29(2), pp.156-170 .